With healthier finances, Clover Bio shifts to flu and RSV vaccines
The Chinese vaccine developer rebounded from a deep loss into profit in the first half of the year, boosted by a one-off gain from a Covid research grant Key Takeaways:…
Recent Articles
RELATED ARTICLES
-
Health Guard plans dual listing to fund HPV vaccine fight
-
WuXi Bio prescribes share buyback to relieve revenue pain
2269.HK
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Goldwind’s profit tumbles as China sales start to deflate
2208.HK 002202.SHE
- CHINA BULLETIN: Services, Trade Send Positive Signals
